Abbott Partners with AtaCor Medical to Develop Next-Generation Extravascular ICD System to Challenge Medtronic's Dominance

Abbott announced withAtaCorReach cooperation to jointly develop the next generation of investigational extravascular implantable cardioverter defibrillator (EV-ICD) system, i.e.AtaCor's extravascular EV-ICD lead (Atala) is paired with the Abbott ICD system.

Executive Evaluation

"Abbott is committed to advancing transformative therapies in the field of cardiac rhythm management. From Abbott's revolutionary AVEIR leadless pacemaker, to the progress in conduction system pacing (CSP) technology, to the potential of the next-generation EV-ICD today, Abbott is redefining the possibilities for improving patient care on a global scale."

---Randel Woodgrift  Senior Vice President of Abbott's Cardiac Rhythm Management Business

ICD is a device implanted by doctors for people at high risk of cardiac arrest and other life-threatening arrhythmias. Traditional ICD leads connect to the heart and monitor its rhythm to help detect dangerous arrhythmias. The collaboration between Abbott and AtaCorExternal Vascular Defibrillator (EV-ICD) adopts a minimally invasive approach, combining the advantages of traditional ICDs with innovative design improvements, which can prevent complications such as vascular injury, lead fractures or malfunctions, and lead infections. By placing the lead components outside the heart and vascular system, this method is expected to address long-standing lead management challenges and may reduce the need for complex corrective surgeries due to transvenous and across-heart structure lead placements.

Currently ListedEV-ICD is only available from Medtronic.Aurora EV-ICD, this product has been approvedFDA, NMPA, CE approved for marketing.Aurora EV-ICD Launch for AbbottThe ICD product is a game-changer. As one of the top three players in cardiac rhythm management, Abbott must present its own...EV-ICD to counter Medtronic, while maintaining its own position inLeadership in Rhythm Management.

Therefore, this time withAtaCor Collaboration Will Enable Abbott inA Shortcut in EV-ICD Development: Narrowing the Time Gap with Medtronic. As part of the collaboration, AtaCor plans to initiate an IDE clinical study this year.ALARION EV), to evaluateextravascular EV-ICD lead (Atala) and Abbott ICD system。

PI Evaluation

"Abbott's AtaCor investigational system represents an exciting advancement in the field of cardiac care, with its ease of implantation and the potential to deliver ICD therapy outside the heart while maintaining contact with cardiac tissue, offering a significant new treatment option for patients in need of life-saving protective measures."

---Paul Friedman  Mayo Clinic

• Unlike subcutaneous ICDs that cannot provide anti-tachycardia pacing (ATP) therapy, Atala achieves both ATP and shock therapy through a single lead and a single procedure.
• AtalaSpecifically designed to enhance patient comfort, it is compatible with smaller and thinner commercially available transvenous ICDs (compared to subcutaneous ICDs). This feature not only improves the aesthetic appearance and comfort after device implantation but also significantly reduces pain perception during ATP therapy.
• AtalaAdvancing Cardiac Rhythm Management to Higher Standards --- Its proprietary design features optimize the implantation process of extravascular ICD leads while enabling seamless integration of ATP and shock therapy through commercially available transvenous ICDs.